Biotech innovation company Aditxt has submitted two applications to the US Food and Drug Administration (FDA) seeking emergency use authorisation (EUA) for its AditxtScore for COVID-19 tests.
The new lab-developed blood test is designed to measure the quantity and quality of Covid-19 antibodies present in the body, including those for its common variants, such as Omicron.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It provides a comprehensive profile of the protective immunity against Covid-19 in the body.
The company said that its immune profile technology AditxtScore for COVID-19 also seeks to explore the difference in response to Covid-19 common variants.
It submitted the applications to the FDA for its AditxtScore for COVID-19 tests, which are designed to measure the level of antibodies that can attack different virus targets, including the spike and nucleocapsid proteins, and reveal levels of antibodies that neutralise Covid-19.
Aditxt co-founder and CEO Amro Albanna said: “Understanding the levels of antibodies to Covid-19 and the effectiveness of these antibodies to neutralise the virus is key to a successful national and global response to the pandemic.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“AditxtScore for COVID-19 and its decoding of the immune response to SARS-CoV-2 plays a vital role in providing such critically needed information and helping us return to normality.”
During the FDA review, the availability of AditxtScore for COVID-19 will continue.
With the help of AditxtScore for COVID-19, individuals will be able to get a better understanding of their immunity status.
Last year, the company launched the AditxtScore Immune Monitoring Center in Richmond, Virginia.
The facility was certified by the Clinical Laboratory Improvement Amendments (CLIA).
